Übersicht – Melanome – Prävention und Screening

• Literatur

• 1 Krebs in Deutschland 2011/2012. 10. Ausgabe. Berlin: Robert Koch-Institut (Hrsg.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg.); 2015
• 2 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens: Radiation. 2012
• 3 Castilla EE, da Graca Dutra M, Orioli-Parreiras IM. Epidemiology of congenital pigmented naevi: II. Risk factors. Br J Dermatol 1981; 104: 421-427
• 4 Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41: 2040-2059
• 5 Eisemann N, Jansen L, Holleczek B et al. Up-to-date results on survival of patients with melanoma in Germany. Br J Dermatol 2012; 167: 606-612
• 6 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3 – Leitlinie Prävention von Hautkrebs, Langversion 1. 1, 2014, AWMF Registernummer: 032/052OL. leitlinienprogrammonkologie.de/Leitlinien.7.0.html (Zugriff am 20. 07. 2016)
• 7 Morrison AS. Screening in chronic disease. Oxford: University Press; 1992
• 8 Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization; 1968
• 9 Andermann A, Blancquaert I, Beauchamp S et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86: 317-319
• 10 Truyers C, Lesaffre E, Kellen E et al. Malignant melanoma: to screen or not to screen? An evaluation of the Euromelanoma Day in Belgium. Eur J Dermatol 2010; 20: 517-518
• 11 Seidenari S, Benati E, Ponti G et al. Italian Euromelanoma Day Screening Campaign (2005–2007) and the planning of melanoma screening strategies. Eur J Cancer Prev 2012; 21: 89-95
• 12 http://www.aad.org/public/spot-skin-cancer/programs/screenings/30-years-of-skin-cancer-awareness (Zugriff am 20. 07. 2016)
• 13 Aitken JF, Elwood JM, Lowe JB et al. A randomised trial of population screening for melanoma. J Med Screen 2002; 9: 33-37
• 14 Aitken JF, Elwood M, Baade PD et al. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer 2010; 15: 450-458
• 15 Anders MP, Nolte S, Waldmann A et al. The German SCREEN project – design and evaluation of the communication strategy. Eur J Public Health 2015; 25: 150-155
• 16 Katalinic A, Waldmann A, Weinstock MA et al. Does skin cancer screening save lives? An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012; 118: 5395-5402
• 17 Breitbart EW, Waldmann A, Nolte S. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012; 66: 201-211
• 18 Eisemann N, Waldmann A, Katalinic A. Inzidenz des malignen Melanoms und Veränderung der stadienspezifischen Inzidenz nach Einführung eines Hautkrebsscreenings in Schleswig-Holstein. Bundesgesundheitsblatt 2014; 57: 77-83
• 19 Katalinic A, Eisemann N, Waldmann A. Skin cancer screening in Germany – documenting melanoma incidence and mortality from 2008 to 2013. Dtsch Arztebl Int 2015; 112: 629-634
• 20 Stang A, Joeckel KH. Does skin cancer screening save lives? A Detailed Analysis of Mortality Time Trends in Schleswig-Holstein and Germany. Cancer 2016; 122: 432-437
• 21 Choudhury K, Volkmer B, Greinert R et al. Effectiveness of skin cancer screening programs. Br J Dermatol 2012; 167 (Suppl. 02) 94-98
• 22 Breitbart EW, Choudhury K, Anders MP et al. Benefits and risks of skin cancer screening. Oncol Res Treat 2014; 37 (Suppl. 03) 38-47
• 23 Veit C, Lüken F, Melsheimer Q. Evaluation der Screeninguntersuchungen auf Hautkrebs gemäß der Krebsfrüherkennungs-Richtlinien des Gemeinsamen Bundesausschusses – Abschlussbericht 2009–2010. BQS Institut für Qualität und Patientensicherheit GmbH; 2015
• 24 Boniol M, Autier P, Gandini S. Melanoma mortality following skin cancer screening in Germany. BMJ Open 2015; 5: e008158